LXEO: Lead gene therapy programs advance toward pivotal milestones with strong efficacy and commercial focus
Lead programs in Friedreich's ataxia and PKP2 cardiomyopathy show strong clinical progress, with pivotal and phase I studies exceeding key efficacy thresholds and favorable safety. Regulatory and commercial strategies are streamlined, with major data and filing milestones expected through 2028.Base…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.